BML Capital Management’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

BML Capital Management’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-248,702	Closed	-$460K	–	32
2024 Q3	$460K	Buy	248,702 +205,959	+482%	+$1.4M	0.27%	24
2024 Q2	$370K	Hold	42,743	–	–	0.26%	28
2024 Q1	$374K	Hold	42,743	–	–	0.25%	31
2023 Q4	$318K	Buy	+42,743	New	+$279K	0.24%	35

Other funds holding TLIS

SAM

Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return

BML Capital Management's TLIS Position: Q4 2024 in Review

BML Capital Management sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q4 2024, closing a stake of 248,702 shares — an estimated $460K sold.

BML Capital Management first reported a position in TLIS in Q4 2023 and held it in 4 quarters. The position peaked at $460K in Q3 2024. 1 fund tracked by Wall St. Rank holds TLIS as of Q4 2024.

BML Capital Management reported no remaining Talis Biomedical Corporation Common Stock position as of Q4 2024 after selling out during the quarter.
BML Capital Management sold 248,702 Talis Biomedical Corporation Common Stock shares in Q4 2024, an estimated $460K.
BML Capital Management first reported a position in Talis Biomedical Corporation Common Stock in Q4 2023 and held it in 4 quarters.
BML Capital Management's Talis Biomedical Corporation Common Stock position peaked at $460K in Q3 2024.
1 fund tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2024.

Based on BML Capital Management's 13F filing for Q4 2024, filed 7 Feb 2025.